Business Wire

South Africa and France Lead the Way in Public and Private Sector Gender Diversity, Latest Research by Kearney Reveals

2.3.2021 17:00:00 EET | Business Wire | Press release

Share

The latest ‘Gender Equality Report’ from Kearney has revealed progress in the representation of women in both public and private sectors, but the figures still don’t show parity.

Ahead of International Women’s Day, the analysis provides insight into the progress of gender diversity in private and public sectors across nine countries – the United States, United Kingdom, Australia, India, France, Spain, Germany, South Africa and Singapore.

The annual report revealed that France was number one for representation in the private sector with women comprising nearly 44% (43.8%) of board members on average, however only 2% of these women held top board positions. The UK (36%) and Australia (34%) also scored highly for representation of women on boards. The average for board level representation of women is 29.9% - not even one in three.

% Female board level representation by country

France

43.8%

UK

36.0%

Australia

34.0%

Germany

32.5%

Spain

29.8%

US

29.8%

South Africa

28.5%

Singapore

17.3%

India

17.0%

The public sector – meaning members of Parliament or equivalent – is faring slightly better. The average across the countries surveyed is 33.2% - a marginal difference compared to the private sector – but two thirds (6 out of 9) countries showed more promising gender parity in their governments compared to on their boards. South Africa led the way in the public sector with 44% of its MPs being women – a huge step up from its 28.5% parity at board level – though France is the most gender-diverse nation when taking an average across both its parliament and the boards of its largest companies. The average across both sectors is 32% female representation, whereas France is a leader with 40.4% parity overall.

% Female parliament representation by country

South Africa

44.0%

Spain

42.0%

Australia

38.0%

France

37.0%

UK

34.0%

Germany

33.0%

Singapore

30.0%

US

27.0%

India

14.0%

This year’s annual report demonstrates modest progress compared with 2020. Representation of women in the private sector has increased marginally in the United States (1.2%), United Kingdom (3%) and Australia (0.6%), as well as in the parliaments in Australia (1%) and the United States (3.5%), which had a record year for women elected. India remains the least gender diverse country studied with representation of women under 20% across both public (14%) and private sectors (17%).

Beth Sehgal, global director of diversity, equity, and inclusion at Kearney, comments:

“It’s positive to see businesses and governments move towards equal representation as women hold an increasing number of high-ranking positions. However, progress has been slow, and the gender leadership gap endures. France is leading the way for private sector representation and South Africa ranks number one for public sector diversity, and the progress of these two countries should provide benchmarks as we work towards achieving gender parity worldwide.

“Diversity, Equity and Inclusion initiatives will need to be prioritized, particularly in countries lagging behind. Diversity has regularly been linked to high-performance with a variety of perspectives encouraging fresh ideas and preventing the dreaded group think. As the economy rebuilds from the aftermath of coronavirus, it will be crucial women are fairly represented in both public and private sector roles to help assist in its recovery and to avoid a regression on gender equality or “she-cession”.”

About Kearney

As a global consulting partnership in more than 40 countries, our people make us who we are. We’re individuals who take as much joy from those we work with as the work itself. Driven to be the difference between a big idea and making it happen, we help our clients break through. Learn more at Kearney.com.

About the research

Kearney‘s Gender Equality Report 2021 was based on research using publicly available data across nine countries – UK, US, France, Germany, Spain, Australia, India and Singapore – regarding the representation of women at board level and in their respective parliaments. Board information was gathered using the support of Factset.

Read the report: https://www.kearney.com/web/international-womens-day/article/?/a/the-equality-dilemma

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press contact
Sophie Mellish
Rostrum – PR consultants to Kearney
s.mellish@rostrum.agency
+44 7789 712 597

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and

Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release

Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila

PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release

Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli

Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release

Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into

Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye